Get all premium features to the best stock analysis tool

FCPM III Services bought 1,489,096 RAPT shares last quarter. The quarter-end position value rose by $53.22 million, reflecting both trading and stock price movement.

OrbiMed Advisors increased its position in RAPT Therapeutics by 556,273 shares during the fourth quarter; the estimated trade size was $17.28 million based on quarterly average pricing. The quarter-end value of the RAPT stake rose by $27.62 million, reflecting both additional shares and stock price appreciation.

Great Point Partners acquired 581,187 shares of RAPT Therapeutics in the fourth quarter. The quarter-end position value increased by $19.68 million due to the new position in RAPT Therapeutics.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of RAPT Therapeutics, Inc. (NasdaqGM: RAPT) to GSK plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of RAPT will receive $58.00 in cash for each share of RAPT that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or.

Shareholders should contact the firm as there may be limited time to enforce your rights Shareholders should contact the firm as there may be limited time to enforce your rights

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of RAPT Therapeutics, Inc. (NasdaqGM: RAPT) to GSK plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of RAPT will receive $58.00 in cash for each share of RAPT that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or.

GSK agrees to buy RAPT Therapeutics for $2.2B, adding ozureprubart to its pipeline and strengthening its respiratory and immunology portfolio.